Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BPGM | P07738 | 1/20 | 0.38 |
| ▸ | PI4KB | Q9UBF8 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | XDH | P47989 | 1/20 | 0.32 |
| ▸ | GPR52 | Q9Y2T5 | 2/20 | 0.32 |
| ▸ | HPGDS | O60760 | 1/20 | 0.31 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.31 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.31 |
| ▸ | RORC | P51449 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24272083 | 0.89 | BPGM (0.49) | BPGMMEN1KMT2AGAAXDH | |
| SCHEMBL24271954 | 0.89 | BPGM (0.38) | BPGMPI4KBGPR52 | |
| SCHEMBL24272012 | 0.86 | BPGM (0.39) | BPGMPI4KBMEN1KMT2AGAA | |
| SCHEMBL24271860 | 0.85 | BPGM (0.51) | BPGMPI4KBMEN1KMT2AGAA | |
| SCHEMBL24272064 | 0.84 | GPR52 (0.35) | BPGMMEN1KMT2AGAAXDH | |
| SCHEMBL24348537 | 0.82 | BPGM (0.40) | BPGMPI4KBGPR52 | |
| SCHEMBL24271892 | 0.82 | BPGM (0.36) | BPGMMEN1KMT2AGAAXDH | |
| SCHEMBL24272076 | 0.82 | GPR52 (0.43) | GPR52RORC | |
| SCHEMBL24271935 | 0.81 | BPGM (0.42) | BPGMPI4KBMEN1KMT2AGAA | |
| SCHEMBL24272062 | 0.81 | MEN1 (0.44) | MEN1KMT2AGAAXDHHPGDS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230348450-A1 | CARBOXYLIC ACID-CONTAINING COMPOUNDS AS MODULATORS OF BIS-PHOSPHOGLYCERATE MUTASE FOR THE TREATMENT OF SICKLE CELL DISEASE | GENZYME CORPORATION | 2023-11-02 | — | — | US | disclosed |
| US-20230348450-A1 | CARBOXYLIC ACID-CONTAINING COMPOUNDS AS MODULATORS OF BIS-PHOSPHOGLYCERATE MUTASE FOR THE TREATMENT OF SICKLE CELL DISEASE | GENZYME CORPORATION | 2023-11-02 | — | — | US | disclosed |
| WO-2022056447-A1 | CARBOXYLIC ACID-CONTAINING COMPOUNDS AS MODULATORS OF BIS-PHOSPHOGLYCERATE MUTASE FOR THE TREATMENT OF SICKLE CELL DISEASE | GENZYME CORPORATION (US) | 2022-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230348450-A1 | CARBOXYLIC ACID-CONTAINING COMPOUNDS AS MODULATORS OF BIS-PHOSPHOGLYCERATE MUTASE FOR THE TREATMENT OF SICKLE CELL DISEASE | BPGM, PGAM1, PGM2 | BPGM 1/4885PI4KB 1398/4885MEN1 3174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.